Biopharmaceutical Industry in China, 2004

Biopharmaceutical Industry in China, 2004

Chapter One: Definition, classification and characteristics of the biopharmaceutical industry
1.1.Definition and classification
1.2.Index analysis of biomedicine
1.2.1. High technology
1.2.2. Large investment
1.2.3. Long periodicity
1.2.4. High risks
1.2.5. High profitability
1.2.6. Obstacles to enter
1.2.7. Growth of the industry
1.3.Related industries’ development
1.3.1. Sector of biomedical engineering
1.3.2. Sector of biomedical materials
1.3.3. Medical treatment packaging industry
1.3.4. Biochip industry



Chapter 2.Development of the international biopharmaceutical industry
2.1.Global biopharmaceutical market scale
2.1.1. Characteristics of the overseas biopharmaceutical industry’s development
2.1.2. General scale of the global biopharmaceutical industry
2.2.Listed biotech companies in the world
2.2.1. Operation analysis
2.2.2. Major biopharmaceutical companies’ operation status in 2003.
2.3.Status of major biopharmaceutical markets in the world
2.3.1. General situation
2.3.2. Global gene engineering industry
2.3.3. Analysis and forecast of the therapeutic albumen market, 2002-2010
2.4.Trends of global biopharmaceutical industry
2.4.1. Forecasts
2.4.2. The best-selling biomedicine products
2.4.3. Medicines that are under development and will soon be put into production



Chapter 3.Operation status of the biopharmaceutical industry in major regions
3.1.The United States
3.1.1. American biotechnology saw a rise in 2003
3.1.2. Biotech companies become the investment focus
3.2.Japanese biopharmaceutical industry
3.2.1. Introduction
3.2.2. Long-term scale of Japanese biotech industry
3.2.3. Achievements of Japan’s protein structure research
3.3.European biopharmaceutical industry
3.3.1. Market share of biomedicine products
3.3.2. Development characteristics of European biotech enterprises
3.4.German biopharmaceutical industry
3.5.Denmark biopharmaceutical industry



Chapter 4.Analysis of China’s pharmaceutical industry in 2003
4.1.General operation status of the pharmaceutical industry
4.1.1. Definition and classification of the industry
4.1.2. Summary of the operation status of China's pharmaceutical industry in 2003
4.2.Changes in the number of pharmaceutical enterprises
4.2.1. Changes in the number of pharmaceutical enterprises and the situation of its sub-industries. 2001-2003, by State Statistical Bureau
4.2.2. Changes regarding the number of pharmaceutical enterprises from 2001 to 2003
4.2.3. Changes regarding the number of pharmaceutical subsidiary enterprises, monitored by SETC
4.3.Analysis on the output value, profits, sales revenue growth of the pharmaceutical industry
4.3.1. Analysis on the general situation of the pharmaceutical industry, 2001-2003
4.3.2. Analysis on the pharmaceutical sub-industries., 2001-2003
4.3.3. Analysis on the profits and losses of pharmaceutical industry and its sub-industries, 2001-2003



Chapter 5.China’s biopharmaceutical industry
5.1.Operation status of China’s biopharmaceutical industry, 2003
5.1.1. Comparison analysis of China’s biopharmaceutical industry, 2001-2003
5.1.2. Operation status of China’s biopharmaceutical industry, 2003
5.1.3. Operation status of China’s biopharmaceutical industry, 2002
5.1.4. Operation status of China’s biopharmaceutical industry, 2001
5.2.Operation status of different types of biopharmaceutical enterprises
5.2.1. Enterprises in different scales
5.2.2. Enterprises in different economic types



Chapter 6. Regional Analysis on the biopharmaceutical industry
6.1.Overall comparison
6.1.1. Regional output ranking according to current production value, 2003
6.1.2. Regional output ranking by according to current production value, 2002
6.1.3. Comparison analysis on the performances of different regions in 2003
6.2.Operation status of the biopharmaceutical industry in Hubei, 2003
6.3.Operation status of the biopharmaceutical industry in Zhejiang, 2003
6.4.Operation status of the biopharmaceutical industry in Shandong, 2003
6.5.Operation status of the biopharmaceutical industry in Shanghai, 2003
6.6.Operation status of the biopharmaceutical industry in Guangdong, 2003
6.7.Operation status of the biopharmaceutical industry in Beijing, 2003
6.8.Operation status of biopharmaceutical industry in Tianjin, 2003
6.9.Operation status of biopharmaceutical industry in Jiangsu, 2003



Chapter7. Market segmentation of China’s biopharmaceutical industry
7.1.Analysis of the major products sales
7.1.1. Sales of major biomedical drugs
7.1.2. R&D of the gene engineering medicine
7.2.Production and sales of domestic interferon market
7.2.1. Major interferon types
7.2.2. Big market space
7.2.3. Competition is getting fiercer
7.2.4. Time is needed for growing
7.2.5. Current listed interferon companies
7.3.Vaccine market
7.3.1. Domestic vaccine market contains great commercial opportunities
7.3.2. Current status of domestic vaccine manufacturers
7.3.3. Influenza vaccine market
7.3.4. Hepatitis B virus vaccine market
7.4.Other market segments
7.4.1. Human blood albumin
7.4.2. Erythropoietin
7.4.3. Interleukin
7.4.4. Colony stimulating factor
7.4.5. Human growth hormone
7.4.6. Insulin



Chapter 8.Biomedicine imports and exports
8.1.Major products imported, 2003
8.2.Major products exported, 2003
8.2.1. Total exports
8.2.2. Major export destinations, export quantity and value



Chapter 9.Operation status of China’s leading biopharmaceutical enterprises
9.1.Ranking
9.1.1. Sales revenue and profits of the top 10 enterprises (ranking by sales revenue), 2003
9.1.2. Top 200 biopharmaceutical enterprises (in terms of sales revenue), by State Statistical Bureau 2002
9.1.3. Top 200 biopharmaceutical enterprises (in terms of profits), by State Statistical Bureau
9.1.4. Top 100 biopharmaceutical enterprises in terms of sales revenue and profits, by SETC
9.2.Operation status of the listed biopharmaceutical companies
9.3.Case study: Beijing TIANTAN Biological Products Co,. Ltd
9.3.1. General information
9.3.2. Analysis on its operations in 2003



Chapter 10.Recommendations for biopharmaceutical investment
10.1.Blank points of the biopharmaceutical investment
10.2.Biopharmaceutical investment and financing strategy
10.2.1. Investment strategy in the United States
10.2.2. Types of biopharmaceutical investment in China
10.2.3. Venture capital investment applies in biopharmaceutical industry
10.2.4. Advance and retreat principle of biopharmaceutical investment






--------------------------------------------------------------------------------
Selected Figures and tables
--------------------------------------------------------------------------------
General market scale of biotech industry, 1994-2003
Increasing trends of pharmaceutical industry’s profitability, by month in 2003
Enterprise number of each China’s pharmaceutical sub-industry
Proportion of pharmaceutical sub-industries by production value
Sales revenue of the pharmaceutical industry and its sub-industries
Profitability of the pharmaceutical industry and its sub- industries
Production value, sales revenue and profit growth of China’s biopharmaceutical industry, 2000-2003
Increase rate of insulin market
Major biopharmaceutical products’ import quantity and value
Characteristics of the biopharmaceutical industry
Ranking of the global top 500 pharmaceutical and biotech companies
Comparison of biotech industry between 2001 and 2002
Biopharmaceutical products with higher market shares
Medicines that will be put into production in the next three years
Basic operational status of China’s pharmaceutical industry, 2003
Sales revenue and profits of the top 10 biopharmaceutical enterprises, 2003
Selected listed biopharmaceutical companies
Benefit status of major pharmaceutical sub-industries, 2003
Important agreements signed by biotech and pharmaceutical companies in 2003
Major biopharmaceutical products’ export quantity and value
Major export destinations, quantity, value and average price of vaccines for human medicine
Major export destinations, quantity, value and average price of vaccines for animal medicine